Use access key #2 to skip to page content.
$0.08 0.00 (0.00%)
8/15/2008 4:00 PM

Genitope Corp (GTOP)

CAPS Rating:
**

A biotechnology company focused on the research and development of novel immunotherapies for the treatment of cancer.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

Ticker Not Ratable

GTOP doesn't currently meet the $100M market cap / $1.50 stock price minimum. (Learn More)

What the Community Thinks

Total Members

51 Outperforms
9 Underperforms
 

All-Stars

6 Outperforms
4 Underperforms
 

Wall Street

0 Outperforms
1 Underperforms
 

Members bullish on GTOP are also bullish on:

Members bearish on GTOP are also bearish on:

Ticker Tags

Biotechnology (294), Cancer Drugs (6), Micro Cap (4824)
Suggest a tag

Genitope Corp At A Glance

Current Price: $0.08
Last Trade Time: 8/15/2008 4:00 PM
Open: $0.00
Previous Close: $0.08
Daily Range: $0.06 - $0.12
52-Week Range: $0.04 - $77.50
Volume: 1,662,680
Market Cap: $2.58M
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

GTOP VS S&P 500 (SPY)

GTOP 12 month chart vs. S&P

News & Discussion Boards

Sorry no news articles available for GTOP.

Top Bull Pitch

Recs

1

Genitope Corp (GTOP)

Avatar PotatoCapital (< 20) Submitted: 12/19/07 11:01 PM

We have a runner!

Replies: 1 | Reply | Permalink

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 14 :   1 2 3 Next »

Show Pitch Replies

Recs

0

 (GTOP)

Avatar skibum0626 (60.95) Submitted: 6/24/08 11:21 AM : Outperform Start Price: $4.10 GTOP Score: -86.65

Seemed like a good pick at the time, had lots of potential, now just hoping for a buyout to save my score..

Report this Post Replies: 0 | Reply | Permalink

Recs

1

 (GTOP)

Avatar PotatoCapital (< 20) Submitted: 12/19/07 11:01 PM : Outperform Start Price: $4.03 GTOP Score: -86.68

We have a runner!

Report this Post Replies: 1 | Reply | Permalink

Recs

0

 (GTOP)

Avatar matstao (99.70) Submitted: 11/29/07 6:01 PM : Outperform Start Price: $4.19 GTOP Score: -85.44

speculative biotech gamble

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (GTOP)

Avatar barnesa13 (< 20) Submitted: 11/27/07 4:20 PM : Outperform Start Price: $4.64 GTOP Score: -88.57

Approval of MyVax

Report this Post Replies: 0 | Reply | Permalink

Recs

1

 (GTOP)

Avatar jogger21 (< 20) Submitted: 11/21/07 10:06 AM : Outperform Start Price: $4.49 GTOP Score: -89.25

The phase 3 trial results will be available by year end 2007. Past results have shown a cure rate for cancer in excess of 42%. If phase 3 results are the same as phase 2, the FDA will approve. Technonogy should also work on other forms of cancer. Look for buy out by major biotech company if results are good.

Report this Post Replies: 1 | Reply | Permalink

Results 1 - 5 of 14 :   1 2 3 Next »

Wall Street

Results 1 - 1 of 1  

picks per page. CHANGE

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackJimCramer 81.79 03/13/06 Underperform 3W $8.82-99.09%+0.85%+99.94

Results 1 - 1 of 1  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners